News

Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced a…
Read More...

Pierre Fabre, the second largest privately held pharmaceutical company in France, and H-Immune SAS, an emerging biotechnology company focused on developing first in class…
Read More...

argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today…
Read More...

Pulmatrix a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced that it has received a key patent from the…
Read More...

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced…
Read More...

Novaliq, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced…
Read More...

Mallinckrodt plc, a leading specialty pharmaceutical company, announced today it has closed the sale of its Intrathecal Therapy business to Piramal Enterprises Limited's subsidiary in…
Read More...

Bristol-Myers Squibb Company and CytomX Therapeutics, Inc., a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, today announced an…
Read More...

Longer-term use of the oral blood thinner Xarelto significantly cut the risk of recurrence of potentially life-threatening blood clots with no additional major bleeding compared with…
Read More...

Oxford BioDynamics is participating in a collaboration to identify the biological factors that trigger disease relapses, known as flares, in Rheumatoid Arthritis (RA), entitled the…
Read More...

Threshold Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapies for cancer, and Molecular Templates, Inc., a privately held biopharmaceutical…
Read More...

Acura Pharmaceuticals, Inc. and MainPointe Pharmaceuticals, LLC announced that they have entered into a License Agreement (the "Agreement") to have MainPointe exclusively market NEXAFED…
Read More...

Alkermes plc announced the initiation of a new phase 3 study of ALKS 8700, a novel, oral monomethyl fumarate (MMF) prodrug candidate in development for the treatment of relapsing forms…
Read More...

Israeli biotechnology company Kadimastem, announced that it has been granted a patent from the United States Patent and Trademark Office for its technology in the field of cell based…
Read More...

PTC Therapeutics, Inc. announced it has entered into an asset purchase agreement with Marathon Pharmaceuticals, LLC to acquire all rights to Emflaza™ (deflazacort). Emflaza is the first…
Read More...

Glycyx PharmaVentures Ltd., a biopharma investment and development company founded by Lorin K. Johnson, Ph.D., has agreed to enter into an exclusive license agreement with Valeant…
Read More...

Ferring Pharmaceuticals and Brazil-based Instituto de Ciências Farmacêuticas (ICF) today announced a research collaboration aimed at developing a mucoadhesive rectal delivery system to…
Read More...

Trovagene, Inc., a precision medicine biotechnology company, and Nerviano Medical Sciences, S.r.l., a leading oncology discovery organization, today announced that they have signed a…
Read More...

Life science researchers working across many applications can now benefit from the first-ever web-based pipetting application, developed to enable seamless connectivity with electronic…
Read More...

The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Sanofi’s dupilumab, an investigational treatment for atopic dermatitis (AD), a positive scientific…
Read More...